Combination Therapy in Pulmonary Arterial Hypertension: Gleaning a Practical Approach from the Randomized Trials

Abstract

In the past decade, combination therapy in pulmonary arterial hypertension (PAH) has evolved from something PAH practitioners felt almost compelled to do, notwithstanding the absence of data, to a strategy proven by well-conducted randomized clinical trials. Whereas in the past, PAH treatment was limited to parenteral epoprostenol; today multiple drugs administrable either parenterally, inhaled, or orally have expanded the options for treating PAH patients. The SERIPHIN, AMBITION, and GRIPHON trials and emerging findings in FREEDOM-EV confirm the validity of a combined-therapy approach. Data from these trials in which either combined therapy was planned or an agent was added to background therapy have demonstrated significant reduction in the progression of disease and are on the cusp of demonstrating survival benefit. Combination therapy may be started simultaneously in some cases, but in many cases a stepped approach to initiating a second, or third, agent is better tolerated. Trials of all the specific combinations of drugs may not be possible, but a continuing trend toward treating PAH with multiple agents is likely. Currently, Food and Drug Administration-approved agents are predominantly pulmonary vasodilators acting through different pathways, with minimal impact on progression of the proliferative pulmonary arteriopathy that is the key pathologic finding in PAH. It is to be hoped that treatment strategies that result in halting progression and substantial reversal of pulmonary arteriolar obstruction will soon be discovered and available.

Keywords

pulmonary arterial hypertension - combination PAH drug therapy - WHO Group 1 PAH - macitentan - ambrisentan - tadalafil - selexipag

• References

• 1 Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ 2018; 360: j5492
• 2 Badesch DB, Raskob GE, Elliott CG. , et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137 (02) 376-387
• 3 Pulido T, Adzerikho I, Channick RN. , et al; SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369 (09) 809-818
• 4 Galiè N, Barberà JA, Frost AE. , et al; AMBITION Investigators. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373 (09) 834-844
• 5 Sitbon O, Channick R, Chin KM. , et al; GRIPHON Investigators. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373 (26) 2522-2533
• 6 Badesch DB, Feldman J, Keogh A. , et al; ARIES-3 Study Group. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther 2012; 30 (02) 93-99
• 7 McLaughlin VV, Badesch DB, Delcroix M. , et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54 (1, Suppl): S97-S107
• 8 McLaughlin V, Channick RN, Ghofrani HA. , et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015; 46 (02) 405-413
• 9 Barst RJ, Rubin LJ, Long WA. , et al; Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334 (05) 296-301
• 10 Hemnes AR. Using omics to understand and treat pulmonary vascular disease. Front Med (Lausanne) 2018; 5: 157
• 11 To the editor. Macitentan and pulmonary arterial hypertension. 1N Engl. J Med 2014; 370: 81-83
• 12 Ghofrani H-A, Galiè N, Grimminger F. , et al; PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369 (04) 330-340
• 13 Tapson VF, Torres F, Kermeen F. , et al. Oral treprostinil therapy for the treatment pulmonary arterial hypertension in patients receiving background endothelin antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012; 142 (06) 1383-1390
• 14 Jing ZC, Parikh K, Pulido T. , et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 2013; 127 (05) 624-633
• 15 Tapson VF, Jing ZC, Xu KF. , et al; FREEDOM-C2 Study Team. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest 2013; 144 (03) 952-958
• 16 Clinical Trials.gov. Trial of the early combination of oral treprostinil with background oral monotherapy in subjects with pulmonary arterial hypertension.
• 17 Rahaghi FF, Feldman JP, Allen RP. , et al. Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulation. Pulm Circ 2017; 7 (01) 167-174
• 18 Sofer A, Ryan MJ, Tedford RJ, Wirth JA, Fares WH. A systematic review of transition studies of pulmonary arterial hypertension specific medications. Pulm Circ 2017; 7 (02) 326-338
• 19 Burks M, Stickel S, Galiè N. Pulmonary arterial hypertension: combination therapy in practice. Am J Cardiovasc Drugs 2018; 18 (04) 249-257
• 20 Simonneau G, Rubin LJ, Galiè N. , et al; PACES Study Group. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2014; 33 (07) 689-697
• 21 Burger CD, Pruett JA, Lickert CA, Berger A, Murphy B, Drake III W. Prostacyclin use among patients with pulmonary arterial hypertension in the United States: a retrospective analysis of a larger health care claims database. J Manag Care Spec Pharm 2018; 24 (03) 291-302
• 22 Dai Z, Zhu MM, Peng Y. , et al. Endothelial and smooth muscle cell interaction via FoxM1 signaling mediates vascular remodeling and pulmonary hypertension. Am J Respir Crit Care Med 2018; 198 (06) 788-802